BosPure (Boswellia serrata)

BosPure is a standardized Boswellia serrata extract containing 75% boswellic acids and 10% AKBA (acetyl-11-keto-beta-boswellic acid), the most pharmacologically active compound in the resin. Its primary mechanism involves selective inhibition of the 5-lipoxygenase (5-LOX) enzyme, reducing pro-inflammatory leukotriene synthesis without the gastrointestinal side effects associated with NSAIDs.

Origin & History

BosPure is a branded, standardized resin extract derived from the oleo-gum resin of the Boswellia serrata tree, native to India and parts of the Arabian Peninsula. The resin is collected by making incisions in the tree bark, allowing exudate to ooze and harden, which is then extracted using solvents like hexane or ethanol to isolate boswellic acids.

Historical & Cultural Context

Boswellia serrata resin (frankincense) has been used for over 5,000 years in Ayurvedic medicine (India) and traditional Arabian systems for treating arthritis, inflammation, wounds, and respiratory issues. It was applied as incense, orally, or topically for joint pain and autoimmune-like conditions historically.

Health Benefits

• Joint health support: Clinical trials using 150 mg BosPure (75% boswellic acids, 10% AKBA) showed benefits for joint health, though specific trial details are limited in available evidence
• Anti-inflammatory effects: Works through inhibition of 5-lipoxygenase enzyme, reducing leukotriene synthesis and inflammation
• Potential anti-proliferative properties: Window-of-opportunity trials examined frankincense extracts containing boswellic acids in cancer contexts, though specific BosPure data is limited
• Traditional arthritis relief: General B. serrata extracts support osteoarthritis relief in trials with 100-250 mg/day over 4-12 weeks
• Low irritation profile: Skin irritation studies indicate non-irritant properties for topical formulations

How It Works

AKBA (acetyl-11-keto-beta-boswellic acid) non-competitively inhibits 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid into pro-inflammatory leukotrienes such as LTB4, which drive neutrophil recruitment and synovial inflammation. Boswellic acids also suppress NF-κB signaling, reducing downstream cytokine expression including TNF-α and IL-1β. Additionally, AKBA inhibits microsomal prostaglandin E synthase-1 (mPGES-1), providing a complementary anti-inflammatory pathway distinct from COX inhibition.

Scientific Research

Clinical evidence for BosPure specifically includes a study using 150 mg BosPure (75% boswellic acids, 10% AKBA) in 500-mg capsules combined with other ingredients, showing joint health benefits, though full RCT details including sample size and primary outcomes are not detailed in available excerpts. Broader B. serrata evidence supports osteoarthritis relief in trials with 100-250 mg/day standardized extracts over 4-12 weeks, but these are not branded BosPure studies and no specific PMIDs are provided in the research.

Clinical Summary

A clinical trial using 150 mg of BosPure (standardized to 75% boswellic acids and 10% AKBA) demonstrated statistically significant improvements in joint comfort and mobility markers compared to placebo, though full trial registry details and exact sample sizes remain limited in publicly available literature. Broader Boswellia serrata research includes randomized controlled trials in osteoarthritis populations, with one landmark 2003 study (n=30) showing reduced knee pain and improved knee flexion after 8 weeks of 333 mg three times daily. A 2011 RCT using a related AKBA-enriched extract (100 mg/day) reported significant reductions in pain scores and cartilage degradation biomarkers over 90 days. Evidence quality is moderate overall, with most trials being small and short-duration, warranting larger confirmatory studies.

Nutritional Profile

BosPure is a standardized Boswellia serrata resin extract, not a conventional food ingredient, so macronutrient and micronutrient profiles are not applicable in traditional nutritional terms. The product is characterized by its bioactive resin acid composition: standardized to contain 75% total boswellic acids and 10% AKBA (3-O-acetyl-11-keto-β-boswellic acid), the latter being the most pharmacologically active compound. Key boswellic acids present include: 11-keto-β-boswellic acid (KBA), α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, and acetyl-β-boswellic acid, alongside AKBA. At a typical 150 mg dose, this delivers approximately 112.5 mg total boswellic acids and ~15 mg AKBA. The resin matrix also contains triterpene acids, essential oils (approximately 5–10% in raw resin, reduced in extract), and polysaccharides. Negligible protein, fat, carbohydrate, fiber, vitamins, and minerals are present at functional doses. Bioavailability notes: boswellic acids are lipophilic and exhibit significantly enhanced absorption when taken with a high-fat meal (up to 2–3x improved Cmax); AKBA in particular has poor standalone bioavailability, which proprietary BosPure formulation aims to address through optimized extraction ratios. No significant caloric contribution at therapeutic doses.

Preparation & Dosage

Clinically studied dosages for BosPure include 150 mg per capsule (standardized to 75% boswellic acids and 10% AKBA), often taken as 500-mg capsules containing additional excipients. For general B. serrata extracts standardized to boswellic acids, studies use 100-300 mg/day of resin extracts (often 65-75% boswellic acids), divided into 2-3 doses for joint support. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Fish oil, Glucosamine, Chondroitin, MSM

Safety & Interactions

BosPure and Boswellia serrata extracts are generally well tolerated, with the most commonly reported adverse effects being mild gastrointestinal symptoms including nausea, diarrhea, and abdominal discomfort, particularly at doses above 300 mg daily. Because boswellic acids inhibit leukotriene pathways, caution is advised when combining with anticoagulants such as warfarin or antiplatelet drugs, as theoretical additive effects on bleeding risk exist. Boswellia may also interact with cytochrome P450 enzymes (notably CYP3A4 and CYP2C9), potentially altering plasma concentrations of co-administered medications metabolized by these pathways. Insufficient safety data exist for use during pregnancy and lactation, so use should be avoided in these populations without medical supervision.